Rapid and Dramatic Radiographic and Clinical Response to an ALK Inhibitor (Crizotinib, PF02341066) in an ALK Translocation-Positive Patient with Non-small Cell Lung Cancer

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

Eunice L. Kwak, Yung‐Jue Bang, D. Ross Camidge et al. · New England Journal of Medicine · 2010 · 4.5K citations

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor <i>EML4-ALK</i>

Alice T. Shaw, Beow Y. Yeap, Mari Mino–Kenudson et al. · Journal of Clinical Oncology · 2009 · 1.9K citations · Full text

Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (<i>ALK</i>) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment

D. Ross Camidge, Scott A. Kono, Antonella Flacco et al. · Clinical Cancer Research · 2010 · 338 citations · Full text

Heterogeneity Basis, Engineering, Pathology +17

ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer

Benjamin Solomon, Marileila Varella‐Garcia, D. Ross Camidge · Journal of Thoracic Oncology · 2009 · 336 citations · Full text

Medicine, New Therapeutic Target, Alk Gene Rearrangements +9

369 Timing of responses to crizotinib (PF-02341066) in anaplastic lymphoma kinase (ALK)-positive patients with advanced non-small cell lung cancer (NSCLC)

Benjamin Solomon, Yu Jeong Bang, D. Ross Camidge et al. · European Journal of Cancer Supplements · 2010 · 10 citations

Medicine, Metronomic Therapy, Immunology +10